Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
Provided By GlobeNewswire
Last update: Nov 24, 2025
Tonix plans to initiate potential pivotal Phase 2 HORIZON study of TNX-102 SL in adults with major depressive disorder in mid-2026
More than 21 million US adults experience a major depressive episode each year
Read more at globenewswire.com
